QuiaPEG Pharmaceuticals operates in medical technology. The company has developed a technological platform that is used to improve and develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio Vitos Norge AS | 25,30 | 25,30 | 2024-12-20 |
| Bo Nordlander | 9,51 | 9,51 | 2025-03-27 |
| Norvolt AS | 7,93 | 7,93 | 2025-03-27 |
| Södra Långudden förvaltning AB | 6,28 | 6,28 | 2025-03-27 |
| Johan Keisu | 2,56 | 2,56 | 2025-03-27 |
| Gunnela Kristina M Blomqvist | 1,81 | 1,81 | 2025-03-27 |
| Olle Svedåker | 1,80 | 1,80 | 2025-03-27 |
| Jeanette Fogelberg | 1,72 | 1,72 | 2025-03-27 |
| Sami Sinno | 1,70 | 1,70 | 2025-03-27 |
| Martin Berglund | 1,48 | 1,48 | 2025-03-27 |
